ICD-10-PCS XW0 New Technology: Anatomical Regions Introduction

List of ICD-10-PCS codes used to specify XW0 - Introduction (putting in or on a therapeutic, diagnostic, nutritional, physiological or prophylactic substance except blood or blood products). There are a total of 44 procedure codes in this section.

ICD-10-PCS Description Status
XW0New Technology, Anatomical Regions, IntroductionNon-Billable Code
XW013W5Introduction of Caplacizumab into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 5Billable Code
XW03321Introduction of Ceftazidime-Avibactam Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 1Billable Code
XW03331Introduction of Idarucizumab, Dabigatran Reversal Agent into Peripheral Vein, Percutaneous Approach, New Technology Group 1Billable Code
XW03341Introduction of Isavuconazole Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 1Billable Code
XW03351Introduction of Blinatumomab Antineoplastic Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 1Billable Code
XW03372Introduction of Inactivated Coagulation Factor Xa into Peripheral Vein, Percutaneous Approach, New Technology Group 2Billable Code
XW03392Introduction of Defibrotide Sodium Anticoagulant into Peripheral Vein, Percutaneous Approach, New Technology Group 2Billable Code
XW033A3Introduction of Bezlotoxumab Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 3Billable Code
XW033B3Introduction of Cytarabine and Daunorubicin Liposome Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 3Billable Code
XW033C3Introduction of Engineered Autologous Chimeric Antigen Receptor T-cell Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 3Billable Code
XW033F3Introduction of Other New Technology Therapeutic Substance into Peripheral Vein, Percutaneous Approach, New Technology Group 3Billable Code
XW033G4Introduction of Plazomicin Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 4Billable Code
XW033H4Introduction of Synthetic Human Angiotensin II into Peripheral Vein, Percutaneous Approach, New Technology Group 4Billable Code
XW033K5Introduction of Fosfomycin Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 5Billable Code
XW033N5Introduction of Meropenem-vaborbactam Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 5Billable Code
XW033Q5Introduction of Tagraxofusp-erzs Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 5Billable Code
XW033S5Introduction of Iobenguane I-131 Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 5Billable Code
XW033U5Introduction of Imipenem-cilastatin-relebactam Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 5Billable Code
XW033W5Introduction of Caplacizumab into Peripheral Vein, Percutaneous Approach, New Technology Group 5Billable Code
XW04321Introduction of Ceftazidime-Avibactam Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 1Billable Code
XW04331Introduction of Idarucizumab, Dabigatran Reversal Agent into Central Vein, Percutaneous Approach, New Technology Group 1Billable Code
XW04341Introduction of Isavuconazole Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 1Billable Code
XW04351Introduction of Blinatumomab Antineoplastic Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 1Billable Code
XW04372Introduction of Inactivated Coagulation Factor Xa into Central Vein, Percutaneous Approach, New Technology Group 2Billable Code
XW04392Introduction of Defibrotide Sodium Anticoagulant into Central Vein, Percutaneous Approach, New Technology Group 2Billable Code
XW043A3Introduction of Bezlotoxumab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 3Billable Code
XW043B3Introduction of Cytarabine and Daunorubicin Liposome Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 3Billable Code
XW043C3Introduction of Engineered Autologous Chimeric Antigen Receptor T-cell Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 3Billable Code
XW043F3Introduction of Other New Technology Therapeutic Substance into Central Vein, Percutaneous Approach, New Technology Group 3Billable Code
XW043G4Introduction of Plazomicin Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 4Billable Code
XW043H4Introduction of Synthetic Human Angiotensin II into Central Vein, Percutaneous Approach, New Technology Group 4Billable Code
XW043K5Introduction of Fosfomycin Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 5Billable Code
XW043N5Introduction of Meropenem-vaborbactam Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 5Billable Code
XW043Q5Introduction of Tagraxofusp-erzs Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 5Billable Code
XW043S5Introduction of Iobenguane I-131 Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 5Billable Code
XW043U5Introduction of Imipenem-cilastatin-relebactam Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 5Billable Code
XW043W5Introduction of Caplacizumab into Central Vein, Percutaneous Approach, New Technology Group 5Billable Code
XW0DX82Introduction of Uridine Triacetate into Mouth and Pharynx, External Approach, New Technology Group 2Billable Code
XW0DXJ5Introduction of Apalutamide Antineoplastic into Mouth and Pharynx, External Approach, New Technology Group 5Billable Code
XW0DXL5Introduction of Erdafitinib Antineoplastic into Mouth and Pharynx, External Approach, New Technology Group 5Billable Code
XW0DXR5Introduction of Venetoclax Antineoplastic into Mouth and Pharynx, External Approach, New Technology Group 5Billable Code
XW0DXT5Introduction of Ruxolitinib into Mouth and Pharynx, External Approach, New Technology Group 5Billable Code
XW0DXV5Introduction of Gilteritinib Antineoplastic into Mouth and Pharynx, External Approach, New Technology Group 5Billable Code